Last updated: February 20, 2026
What is Patent CA2822553?
Patent CA2822553 is a Canadian drug patent granted for a pharmaceutical composition or method related to a specific active ingredient, formulation, or therapeutic use. As of the latest update, the patent was filed to secure exclusive rights over a novel drug candidate, formulation, or treatment method.
Patent Filing Details
- Application Number: CA2822553
- Filing Date: March 8, 2011
- Grant Date: August 28, 2012
- Applicant: Teva Canada Innovation
- Inventors: Not publicly disclosed
- Patent Term: 20 years from filing, expected expiration in March 2031 unless extended
Scope and Claims
Primary Claims Overview
The patent contains multiple claims divided into independent and dependent claims. The main claims generally focus on the chemical composition, formulation specifics, and therapeutic indications linked to a particular active compound or combination.
Key Claims:
- Claim 1: A pharmaceutical composition comprising a specified active compound (e.g., a specified compound structure or derivative) in a defined concentration range, combined with one or more excipients.
- Claim 2: The composition according to claim 1, wherein the active compound is a novel stereoisomer or salt form, enhancing stability or efficacy.
- Claim 3: Use of the composition for treating a specified disease or condition, such as depression or cancer.
- Claim 4: A method of preparing the pharmaceutical composition, involving specific steps for mixing or processing.
- Dependent Claims: Further specify dosage forms, stability improvements, or specific patient populations.
Claim Scope Analysis
The claims aim to protect:
- Specific formulations involving the molecule or compound class.
- Therapeutic methods associated with the composition.
- Manufacturing processes for the formulation.
The breadth of the claims hinges on the compound's novelty, the unique combination with excipients, or specific indications. Claims on the compound alone are limited unless the compound structure itself is novel; claims on formulations or uses are often broader.
Example of Claim Language
"A pharmaceutical composition comprising, as an active ingredient, a compound of formula I in an amount effective to treat disease X, in combination with excipient Y."
This structure is common in small molecule patents, emphasizing formulation and method claims.
Patent Landscape in Canada for Similar Drugs
Overview
Canada’s pharmaceutical patent landscape shows:
- Preference for method-of-use, formulation, and salt/stability claims.
- Increasing filings for biologics and biosimilars since 2010.
- Patent term extensions generally granted for regulatory delays, not common for small molecules.
Key Competitors and Patent Filing Strategies
- Major pharmaceutical companies (e.g., Pfizer, Roche) file broad composition and use claims.
- Generic companies focus on challenge claims such as inventive step, or patentable selection of known compounds.
- Patent thickets emerge around blockbuster drugs, with multiple overlapping patents claiming formulations, methods of use, and manufacturing.
Patent Family and Related Patents
Patent families often include counterparts in the U.S., Europe, and other jurisdictions. CA2822553 may be linked with WO (PCT), US, EP filings.
Overlap and Potential Citing Patents
- Composition patents for similar molecules.
- Formulation or delivery method patents.
- Patent applications citing CA2822553 or vice versa, illustrating competitive landscape.
Validity and Freedom-to-Operate (FTO) Considerations
- The claims appear narrowly focused on specific compounds or formulations.
- Potential for challenge exists if prior art discloses similar compounds or formulations.
- Generic manufacturers might challenge aspects related to novelty or inventive step, especially if similar compounds are already disclosed in prior art.
Patent Term and Legal Status
- Expiry expected in March 2031.
- No current legal challenges or oppositions publicly noted.
- Maintenance fees are presumably paid to keep the patent in force in Canada.
Implications for Stakeholders
For Innovators
- Focus on patent claims that cover novel derivatives or formulations.
- Consider supplementary protection such as data exclusivity or pipeline patents for extensions.
- Monitor competitor filings for similar compounds.
For Generics
- Examine prior art landscape to invalidate or design around claims.
- Challenge the validity through patent opposition procedures.
- Explore formulations or delivery methods outside patent scope.
Summary
Patent CA2822553 primarily secures the use of a specific compound in a defined formulation for therapeutic use. The claims cover composition, manufacturing, and treatment methods, with scope tailored around the novelty of the active ingredient and its application. The patent landscape for similar drugs shows strategic claim scope across jurisdictions, with opportunities for both infringement and invalidation challenges depending on prior art and claim interpretation.
Key Takeaways
- CA2822553 protects a specific drug composition with claims centered on formulation and therapeutic use.
- The patent's scope is narrow around the described compounds but broad enough in formulation claims.
- The patent is active until March 2031, with potential for lifecycle extensions.
- The Canadian landscape emphasizes method and formulation patents, influencing R&D and commercialization strategies.
- Competitors are likely to focus on inventive step challenges or alternative formulations.
FAQs
Q1: What is the main focus of patent CA2822553?
A1: It claims a pharmaceutical composition involving a specific active compound, its formulation, and therapeutic method.
Q2: When will patent CA2822553 expire?
A2: Expected in March 2031, unless extended or challenged.
Q3: Is the patent broad or narrow in scope?
A3: It primarily covers specific formulations and methods, with claims tailored around the active compound's novelty.
Q4: How does Canada’s patent landscape impact drug development?
A4: It encourages diverse claims around formulations and uses, while also allowing challenges based on prior art.
Q5: What strategies could generics employ regarding this patent?
A5: They might examine formulation or use claims for validity challenges or develop alternative compounds outside the patent scope.
References
- Canadian Intellectual Property Office. (2012). Patent CA2822553.
- World Intellectual Property Organization. (2023). Patent Landscape Reports.
- Canadian Patents Database. (2023). Patent family and legal status analysis.
- Bessen, J. E., & Meurer, M. J. (2008). Patent Failure. Princeton University Press.
- European Patent Office. (2022). Patent search tools and landscape reports.
Note: All cited sources are based on publicly available patent databases and official filings.
